7. Factor XI

[1]  G. Lippi,et al.  The use of desmopressin in congenital factor XI deficiency: a systematic review , 2009, Annals of Hematology.

[2]  D. Gailani,et al.  Structural and functional features of factor XI , 2009, Journal of thrombosis and haemostasis : JTH.

[3]  A. Gruber,et al.  Factor XI contributes to thrombin generation in the absence of factor XII. , 2008, Blood.

[4]  T. Walz,et al.  Factor XI Homodimer Structure Is Essential for Normal Proteolytic Activation by Factor XIIa, Thrombin, and Factor XIa* , 2008, Journal of Biological Chemistry.

[5]  P. E. Bock,et al.  Characterization of Novel Forms of Coagulation Factor XIa , 2008, Journal of Biological Chemistry.

[6]  P. McEwan,et al.  Crystal structure of the factor XI zymogen reveals a pathway for transactivation , 2006, Nature Structural &Molecular Biology.

[7]  R. Babine,et al.  Structural and Mutational Analyses of the Molecular Interactions between the Catalytic Domain of Factor XIa and the Kunitz Protease Inhibitor Domain of Protease Nexin 2* , 2005, Journal of Biological Chemistry.

[8]  S. Brown.  What dose of recombinant activated factor VII should be used in patients with factor XI deficiency? , 2005, Haemophilia : the official journal of the World Federation of Hemophilia.

[9]  P. Hopmeier,et al.  Coagulation factor XI: a database of mutations and polymorphisms associated with factor XI deficiency , 2005, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[10]  D. Perry,et al.  The rare coagulation disorders – review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation , 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

[11]  R. Mountford,et al.  A common ancestral mutation (C128X) occurring in 11 non‐Jewish families from the UK with factor XI deficiency , 2004, Journal of thrombosis and haemostasis : JTH.

[12]  D. Kravtsov,et al.  Factor XI apple domains and protein dimerization , 2003, Journal of thrombosis and haemostasis : JTH.

[13]  F. Bauduer,et al.  Factor XI deficiency in French Basques is caused predominantly by an ancestral Cys38Arg mutation in the factor XI gene. , 2002, Blood.

[14]  C. Hermans,et al.  Successful use of recombinant factor VIIa in a patient with inhibitor secondary to severe factor XI deficiency , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

[15]  T. Renné,et al.  Characterization of the H-kininogen-binding Site on Factor XI , 2002, The Journal of Biological Chemistry.

[16]  J. Abgrall,et al.  The use of recombinant factor VIIa (NovoSeven) in a patient with a factor XI deficiency and a circulating anticoagulant. , 2001, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[17]  P. Walsh.  Roles of Platelets and Factor XI in the Initiation of Blood Coagulation by Thrombin , 2001, Thrombosis and Haemostasis.

[18]  P. Walsh,et al.  Localization of a heparin binding site in the catalytic domain of factor XIa. , 2001, Biochemistry.

[19]  P. Walsh,et al.  Noncovalent Interactions of the Apple 4 Domain That Mediate Coagulation Factor XI Homodimerization* , 2001, The Journal of Biological Chemistry.

[20]  L. Aledort,et al.  Obstetrical and gynaecological bleeding: a common presenting symptom. , 2000, Clinical and laboratory haematology.

[21]  J. Meijers,et al.  Role of blood coagulation factor XI in downregulation of fibrinolysis , 2000, Current opinion in hematology.

[22]  Bolton‐Maggs.  Factor XI deficiency and its management , 2000, Haemophilia : the official journal of the World Federation of Hemophilia.

[23]  D. Gailani,et al.  Identification of Amino Acids in the Factor XI Apple 3 Domain Required for Activation of Factor IX* , 1999, The Journal of Biological Chemistry.

[24]  Bolton‐Maggs.  Bleeding problems in factor XI deficient women , 1999, Haemophilia : the official journal of the World Federation of Hemophilia.

[25]  P. Walsh,et al.  A Binding Site for Heparin in the Apple 3 Domain of Factor XI* , 1998, The Journal of Biological Chemistry.

[26]  D. Perry,et al.  Recurrent venous thromboembolic disease and factor XI concentrate in a patient with severe factor XI deficiency, chronic myelomonocytic leukaemia, factor V Leiden and heterozygous plasminogen deficiency. , 1997, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[27]  P. A. von dem Borne,et al.  Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis. , 1997, The Journal of clinical investigation.

[28]  M. Makris,et al.  In vivo coagulation activation following infusion of highly purified factor XI concentrate , 1997, British journal of haematology.

[29]  Yuehui Sun,et al.  Identification of a Factor IX Binding Site on the Third Apple Domain of Activated Factor XI* , 1996, The Journal of Biological Chemistry.

[30]  F. Baglia,et al.  A Binding Site for Thrombin in the Apple 1 Domain of Factor XI (*) , 1996, The Journal of Biological Chemistry.

[31]  J. Huart,et al.  Nanofiltration, a New Specific Virus Elimination Method Applied to High‐Purity Factor IX and Factor XI Concentrates , 1994, Vox sanguinis.

[32]  U. Martinowitz,et al.  Dental extractions in patients with bleeding disorders. The use of fibrin glue. , 1993, Oral surgery, oral medicine, and oral pathology.

[33]  T. Burnouf,et al.  A therapeutic, highly purified factor XI concentrate from human plasma , 1992, Transfusion.

[34]  B. Brenner,et al.  Dental surgery in patients with severe factor XI deficiency without plasma replacement. , 1992, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[35]  E. Mulvihill,et al.  Apple four in human blood coagulation factor XI mediates dimer formation. , 1992, Biochemistry.

[36]  G. Broze,et al.  Factor XI activation in a revised model of blood coagulation , 1991, Science.

[37]  E. Davie,et al.  Factor XI deficiency in Ashkenazi Jews in Israel. , 1991, The New England journal of medicine.

[38]  K. Fujikawa,et al.  Location of the disulfide bonds in human coagulation factor XI: the presence of tandem apple domains. , 1991, Biochemistry.

[39]  S. Schiffman,et al.  Purification and characterization of platelet factor XI. , 1990, Thrombosis research.

[40]  A. McCraw,et al.  Inheritance and bleeding in factor XI deficiency , 1988, British journal of haematology.

[41]  A. Dalmasso,et al.  Factor XI deficiency: Genetic and clinical studies of a single kindred , 1988, American journal of hematology.

[42]  D. Sinha,et al.  THE REGULATION OF FACTOR XIa ACTIVITY BY PLATELETS AND ALPHA-1-PROTEASE INHIBITOR , 1987, Thrombosis and Haemostasis.

[43]  H. Hemker,et al.  Inhibition of factor XIa by antithrombin III. , 1987, Biochemistry.

[44]  D. Sinha,et al.  Role of calcium ions and the heavy chain of factor XIa in the activation of human coagulation factor IX. , 1987, Biochemistry.

[45]  E. Davie,et al.  Organization of the gene for human factor XI. , 1987, Biochemistry.

[46]  D. Sinha,et al.  Mechanism of activation of coagulation factor XI by factor XIIa studied with monoclonal antibodies. , 1986, Journal of Clinical Investigation.

[47]  K. Fujikawa,et al.  Amino acid sequence of human factor XI, a blood coagulation factor with four tandem repeats that are highly homologous with plasma prekallikrein. , 1986, Biochemistry.

[48]  K. Fujikawa,et al.  Human plasma prekallikrein, a zymogen to a serine protease that contains four tandem repeats. , 1986, Biochemistry.

[49]  L. Winkelman,et al.  A Pasteurized Antithrombin III Concentrate for Clinical Use , 1985, Vox sanguinis.

[50]  R. Colman,et al.  Inactivation of factor XIa by plasma protease inhibitors: predominant role of alpha 1-protease inhibitor and protective effect of high molecular weight kininogen. , 1982, The Journal of clinical investigation.

[51]  H. Saito,et al.  Inhibitory spectrum of alpha 2-plasmin inhibitor. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[52]  K. Kurachi,et al.  Activation of human factor XI (plasma thromboplastin antecedent) by factor XIIa (activated Hageman factor). , 1977, Biochemistry.

[53]  A. Kaplan,et al.  Association of factor XI and high molecular weight kininogen in human plasma. , 1977, The Journal of clinical investigation.

[54]  R. Colman,et al.  Identification of prekallikrein and high-molecular-weight kininogen as a complex in human plasma. , 1976, Proceedings of the National Academy of Sciences of the United States of America.

[55]  A. Kaplan,et al.  SUBSTRATES OF HAGEMAN FACTOR : I. Isolation and Characterization of Human Factor XI (PTA) and Inhibition of the Activated Enzyme by α1-Antitrypsin , 1974 .

[56]  R. Rosenthal,et al.  New Hemophilia-like Disease Caused by Deficiency of a Third Plasma Thromboplastin Factor.∗ , 1953, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[57]  N. Ozbek,et al.  Successful Use of Recombinant Factor VIIa (NovoSeven®) During Cardiac Surgery in a Pediatric Patient with Congenital Factor XI Deficiency , 2007, Pediatric Cardiology.

[58]  N. Aoki,et al.  Factor XI gene (F11) is located on the distal end of the long arm of human chromosome 4. , 1989, Cytogenetics and cell genetics.